A Study on the Efficacy and Safety of IPyC for HER2+ MBC

A Retrospective Multicenter Cohort Study on the Efficacy and Safety of Inetetamab and Pyrotinib Combined With Chemotherapy for HER2-positive Metastatic Breast Cancer

Between July 2020 and August 2024, 301 HER2-positive MBC patients from five tertiary centers received the regimen until disease progression or unacceptable toxicity. Efficacy endpoints included progression-free survival (PFS), objective response rate (ORR), and clinical benefit rate (CBR).

Inclusion Criteria:

• patients who underwent a biopsy of the metastatic site and were confirmed as having MBC
• patients who received inetetamab + pyrotinib + chemotherapy as metastasis therapy.

Exclusion Criteria:

• male patients or individuals with prior malignancy
• patients with prior or current enrollment in interventional clinical trials for MBC
• patients who received less than 2 cycles of treatment (6 weeks of inetetamab or 8 weeks of pyrotinib)
• patients who were lost to follow-up during the therapeutic process